Selank vs semax

Semax drives neurotrophin production and works faster. Selank modulates GABA tone and works more subtly. If the research question is acute neuroprotection or cognitive demand, Semax has stronger mechanistic backing. If the question is chronic anxiety modulation with immune crosstalk, Selank fits better.

Quick Comparison

Semax Works Through BDNF and Monoamine Systems — Not ACTH Receptors

Semax is an ACTH fragment, but it does not activate melanocortin receptors the way endogenous ACTH does. Instead, it upregulates brain-derived neurotrophic factor in the basal forebrain and hippocampus, as shown in a 2006 Journal of Neurochemistry study using rat brain tissue. BDNF is the neurotrophin most tightly linked to synaptic plasticity and neuronal survival under stress.

The peptide also modulates dopaminergic and serotonergic signaling. A 2010 study in Neurochemical Research found that Semax increased dopamine turnover in the mesocortical pathway without raising extracellular dopamine levels in the striatum — a pattern that suggests enhanced utilization rather than raw release. This is mechanistically distinct from stimulants, which flood synapses with monoamines.

More recent work shows mu-opioid receptor involvement. A 2017 paper in Molecular Biology reported that Semax binds to mu-opioid receptors in the hippocampus and increases their expression during recovery from spinal cord injury in rats. This adds an opioid-mediated neuroprotective layer that most nootropics lack. Molecular weight: 813.94 Da.

Selank Modulates GABA Tone Without Receptor Binding — It Works Upstream

Selank does not bind GABA-A receptors directly. Instead, it alters GABAergic transmission by influencing the expression and activity of enzymes that regulate GABA synthesis and breakdown. A 2016 Frontiers in Molecular Neuroscience study showed that Selank increased mRNA expression of glutamic acid decarboxylase (GAD), the rate-limiting enzyme that converts glutamate into GABA, in rat hippocampal and cortical tissue.

The peptide also stabilizes endogenous enkephalins by inhibiting enkephalin-degrading enzymes. Enkephalins are endogenous opioid peptides that modulate mood and stress response through delta-opioid receptors. By slowing their degradation, Selank prolongs their inhibitory effects on stress circuits in the amygdala and hypothalamus.

Selank's immune-modulating effects are less studied but consistent. It reduces pro-inflammatory cytokine expression (IL-6, TNF-alpha) in rodent models of chronic stress, which may explain why it shows effects on both anxiety behavior and immune markers simultaneously. Molecular weight: 751.86 Da. For research purposes only, particularly when exploring CNS-immune crosstalk.

Where They Overlap: Both Influence Gene Expression in Stress-Response Pathways

Both peptides modulate gene expression in brain regions tied to stress resilience, but they do so through different transcription factors. Semax activates CREB (cAMP response element-binding protein), a transcription factor downstream of BDNF signaling that drives the expression of synaptic plasticity genes. A 2013 study in Pharmacological Reports showed that Semax increased CREB phosphorylation in rat hippocampus after ischemic injury, correlating with improved spatial memory retention.

Selank influences gene expression through immune-related transcription pathways. A 2014 PLoS ONE study found that chronic Selank administration in mice altered the expression of over 30 genes involved in cytokine signaling and stress response, including downregulation of genes tied to inflammatory cascades. This suggests Selank's effects on behavior may be partially mediated by peripheral immune signaling rather than direct CNS receptor binding.

Neither peptide crosses the blood-brain barrier efficiently in standard formulations — intranasal administration is the most common route in Russian clinical practice, bypassing first-pass metabolism and delivering peptide directly to olfactory bulb pathways. Both have rapid onset but short circulating half-lives, requiring repeated dosing in research protocols.

The Practical Research Decision: Match the Peptide to the Model

Choose Semax when the model involves acute neural injury or cognitive demand. The BDNF upregulation is fast — detectable within hours in rodent models — and the dopaminergic modulation supports working memory and attention in prefrontal cortex-dependent tasks. In a 2011 study published in Bulletin of Experimental Biology and Medicine, Semax reduced infarct size by ~30% in rat middle cerebral artery occlusion models when administered within 6 hours of stroke onset. That effect size is stronger than most neuroprotective peptides in similar paradigms.

Semax also shows utility in attention-deficit models. A small 2010 Russian clinical trial (n=80) in children with attention disorders found measurable improvements on the Bourdon test (a sustained attention task) after 40 days of intranasal Semax. The trial was not placebo-controlled, and the effect size was modest, but it aligns with the mechanistic data on prefrontal dopamine modulation.

Choose Selank when the model involves chronic anxiety, immune dysregulation, or gene expression studies in stress circuits. The GABAergic modulation is gentler than benzodiazepines — no sedation, no receptor downregulation in the studies published to date. A 2008 Human Psychopharmacology study compared Selank to the benzodiazepine gidazepam in patients with generalized anxiety disorder and found comparable symptom reduction on the Hamilton Anxiety Rating Scale, but Selank showed no cognitive impairment or withdrawal effects.

Selank's immune effects make it useful for psychoneuroimmunology research. A 2016 study in Immunology Letters showed that Selank normalized IL-6 and TNF-alpha levels in rats subjected to chronic restraint stress, suggesting it may interrupt the inflammatory feedback loop that sustains anxiety-like behavior. No peptide with pure CNS activity shows this pattern.

If the goal is stacking, the combination is mechanistically complementary — Semax drives BDNF-dependent plasticity while Selank stabilizes inhibitory tone and reduces inflammatory noise. A 2012 Russian study in healthy volunteers (n=30) tested the combination and reported additive effects on working memory tasks and self-rated anxiety scales, though the trial lacked a placebo control and has not been replicated outside Russia.

FAQ

Q: Can Semax and Selank be used in the same research protocol?

Yes, they target different pathways and have been co-administered in Russian clinical settings without reported interactions. Semax works through BDNF and monoamine systems; Selank modulates GABA synthesis and enkephalin degradation. One small 2012 Russian study in healthy subjects reported additive cognitive and anxiolytic effects, though it lacked placebo controls. Mechanistically, the combination addresses both neuroplasticity and inhibitory tone, making it suitable for models that involve both cognitive demand and stress modulation.

Q: Which peptide has stronger human evidence?

Semax has more diverse human data. It has been used clinically in Russia since the 1990s for stroke recovery and cognitive disorders, with published case series and small controlled trials. A 2011 study in stroke patients showed reduced infarct size and faster recovery when Semax was administered within hours of symptom onset. Selank's human data is limited almost entirely to anxiety disorder trials in Russian populations, most of which lack independent Western replication. Both peptides need larger, placebo-controlled trials under Western regulatory standards.

Q: Do either of these peptides raise cortisol or affect the HPA axis?

Semax is derived from ACTH but does not activate melanocortin receptors, so it does not stimulate cortisol release the way full-length ACTH does. A 2008 study in rats confirmed no elevation in plasma corticosterone after Semax administration. Selank has been shown to normalize HPA axis activity in chronic stress models — reducing cortisol when it is elevated but not suppressing it at baseline. A 2014 study in stressed rats showed Selank reduced corticosterone levels back toward control levels without going below them.

Q: What are the typical research dosing ranges?

In rodent models, Semax is dosed at 50-500 mcg/kg intraperitoneally or intranasally, with most neuroprotection studies using the higher end of that range. Human trials in Russia have used 300-900 mcg/day intranasally, divided into 2-3 doses. Selank is typically dosed at 100-300 mcg/kg in rodents and 300-600 mcg/day intranasally in human trials. Both peptides have short half-lives, so research protocols usually involve multiple daily administrations.

Q: Are there stability concerns with intranasal formulations?

Yes. Both peptides degrade rapidly in aqueous solution at room temperature. Lyophilized powder is stable at -20°C for months, but reconstituted solutions should be stored at 4°C and used within 1-2 weeks. Intranasal delivery requires preservative-free formulations to avoid nasal irritation, which limits shelf life further. Some Russian clinical formulations include excipients that stabilize the peptide, but those formulations are not widely available outside Russia.

This article is for informational and research reference purposes only. Semax and Selank are not approved by the FDA for human use in the United States, and neither should be self-administered outside a supervised clinical or research context.